Added to YB: 2026-06-22
Pitch date: 2026-06-19
QURE [bullish]
uniQure N.V.
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$2.9B
Pitch Price
N/A
Price Target
63.73 (+136%)
Dividend
N/A
EV/EBITDA
-17.10
P/E
-13.28
EV/Sales
159.09
Sector
Biotechnology
Category
special_situation
This Biotech Is Up 90% Since My Original Thesis - $QURE
QURE (holding update): Up 90% since Jan thesis; FDA reversed course, allowing 3-yr Phase 1/2 data to support AMT-130 Huntington's Accelerated Approval BLA (Q3 2026). $586.6M cash funds ops into 2H29. Pipeline: AMT-191 Fabry (all 11 off ERT), AMT-260 epilepsy. RWEV ~$63.73 vs $46.29, +38% upside. Risk: now priced for execution.
Read full article (6 min)